Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
Stopped early
Conditions studied: Achromatopsia
In brief
This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia associated with defects in CNGB3 who participated in a clinical trial in which they received AAV-CNGB3 retinal gene therapy.
Key facts
- Study ID
- NCT03278873
- Run by
- MeiraGTx UK II Ltd
- People needed
- 34
- Starts
- 2017-06-29
- Expected to finish
- 2024-04-04
- Last updated by the study team
- 2025-06-11
Who can join
Age: 3 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kellogg Eye Center — Ann Arbor, Michigan, United States
- Moorfields Eye Hospital NHS Foundation Trust — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.